ClearPoint Neuro Inc. (CLPT)
| Bid | 12.99 |
| Market Cap | 389.76M |
| Revenue (ttm) | 31.39M |
| Net Income (ttm) | -18.91M |
| EPS (ttm) | -0.7 |
| PE Ratio (ttm) | -19.9 |
| Forward PE | -22.09 |
| Analyst | Strong Buy |
| Ask | 15.04 |
| Volume | 146,479 |
| Avg. Volume (20D) | 256,656.7 |
| Open | 14.53 |
| Previous Close | 14.39 |
| Day's Range | 13.91 - 14.56 |
| 52-Week Range | 5.11 - 19.22 |
| Beta | 0.98 |
About CLPT
ClearPoint Neuro, Inc. operates as a medical device company primarily in the United States. The company develops and commercializes platforms for performing minimally invasive surgical procedures in the brain under direct, and intra-procedural magnetic resonance imaging (MRI) guidance. It offers ClearPoint system for the insertion of deep brain stimulation electrodes and biopsy needles, and the infusion of pharmaceuticals and laser catheters into...
Analyst Forecast
According to 3 analyst ratings, the average rating for CLPT stock is "Strong Buy." The 12-month stock price forecast is $25, which is an increase of 79.47% from the latest price.
Stock ForecastsNext Earnings Release
Analysts project revenue of ... Unlock content with Pro Subscription
6 days ago · accessnewswire.com
ClearPoint Neuro to Announce First Quarter 2025 Results May 13, 2025SOLANA BEACH, CA / ACCESS Newswire / April 25, 2025 / ClearPoint Neuro, Inc. (NASDAQ:CLPT) (the "Company"), a global device, cell, and gene therapy-enabling company offering precise navigation to the ...
2 months ago · seekingalpha.com
ClearPoint Neuro: Drug Delivery Prospects Continue To StrengthenClearPoint's Q4 results were soft, although lumpy growth should be expected given the nature of ClearPoint's business. Neurosurgery growth remains robust, and the expansion of preclinical and clinical...
2 months ago · accessnewswire.com
ClearPoint Neuro Reports Fourth Quarter and Full Year 2024 ResultsAchieved Record Revenue for 2024 and Growth of 31%; Reduced 2024 Operational Cash Burn by 35% SOLANA BEACH, CALIFORNIA / ACCESS Newswire / February 26, 2025 / ClearPoint Neuro, Inc. (Nasdaq:CLPT) (the...
2 months ago · accessnewswire.com
ClearPoint Neuro to Announce Fourth Quarter and Full Year 2024 Results February 26, 2025SOLANA BEACH, CA / ACCESS Newswire / February 14, 2025 / ClearPoint Neuro, Inc. (NASDAQ:CLPT) (the "Company"), a global device, cell, and gene therapy-enabling company offering precise navigation to t...
2 months ago · accessnewswire.com
ClearPoint Neuro Announces EU MDR Certification for the SmartFlow CannulaSOLANA BEACH, CA / ACCESS Newswire / February 12, 2025 / ClearPoint Neuro, Inc. (Nasdaq:CLPT) (the "Company"), a global device, cell, and gene therapy-enabling company offering precise navigation to t...